$TLRY

Merton Carl A purchased $46K of TLRY

Merton Carl A (Chief Financial Officer) purchased 10,000 shares of Tilray Brands, Inc. (TLRY) at $4.62 on 2026-08-04.

Original reporting
SEC EDGAR · Merton Carl A
Published Aug 4, 2026, 5:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TLRY
Neutral
medium confidence
Mentioned
$TLRY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TLRYNeutralLow
01

Why it matters

The newest fact is the CFO’s open-market purchase details (10,000 shares at $4.62) filed on 2026-08-04; no other company-specific catalyst is included.

02

Market read

Traders may note the insider buy as a mild sentiment input, but the filing alone is unlikely to drive a durable repricing without additional fundamental news.

03

What to watch

The article provides no context on prior insider activity, option exercises, or whether the CFO has ongoing compensation-driven buying patterns.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04 (same day as transaction)

Background

This is an SEC Form 4 insider transaction disclosure for Tilray Brands, Inc.

Company-level read

Ticker impact

$TLRYNeutralMedium confidence
Context

Tilray CFO Merton Carl A filed a Form 4 open-market purchase of 10,000 shares at $4.62 on 2026-08-04.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

Form 4 insider buys can be read as confidence, but the transaction size ($46.2k) is modest versus typical market-moving thresholds, and there is no accompanying guidance, deal, or regulatory event in the text.

Market effects

No sector-level implications are disclosed; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine liquidity or diversification actions, and the absence of a 10b5-1 plan does not guarantee a bullish fundamental thesis.

Key entities

  • Tilray Brands, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Merton Carl A

    Tilray CFO who purchased 10,000 shares open-market at $4.62.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

$TLRYMed

Tilray Brands (TLRY) Is Up 5.7% After Narrower Loss, ESOP Shelf Filing and M&A Signal

Tilray Brands reported Q4 sales of US$281.71 million and full-year sales of US$915.45 million for the year ended May 31, 2026, with a substantially smaller net loss than the prior year. The company also filed a US$47.69 million shelf registration for 11,355,231 common shares tied to its ESOP. Management said at-the-market equity proceeds may fund acquisitions, including deals like BrewDog.

$TLRYMed

Tilray Brands Q4 Earnings Call Highlights

Tilray Brands (NASDAQ: TLRY) reported fiscal 2026 results on its Q4 earnings call. Net loss narrowed to $105.2M ($1.09/share) from about $2.2B in fiscal 2025. Adjusted net income rose 87% to $12.2M. Cannabis and distribution revenue grew, BrewDog added beverage revenue, and Tilray guided adjusted EBITDA of $68M to $75M for fiscal 2027.